Infections in the era of immunobiologicals

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Federal de São Paulo (UNIFESP)-
Autor(es): dc.contributorCentro de Dermatologia Dona Libânia-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversidade Federal Fluminense (UFF)-
Autor(es): dc.creatorRomiti, Ricardo-
Autor(es): dc.creatorHirayama, André Luís da Silva-
Autor(es): dc.creatorPorro, Adriana Maria-
Autor(es): dc.creatorGonçalves, Heitor de Sá-
Autor(es): dc.creatorMiot, Luciane Donida Bartoli-
Autor(es): dc.creatorDurães, Sandra Maria Barbosa-
Autor(es): dc.creatorMarques, Silvio Alencar-
Data de aceite: dc.date.accessioned2025-08-21T18:43:25Z-
Data de disponibilização: dc.date.available2025-08-21T18:43:25Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-03-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.abd.2023.08.004-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/303927-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/303927-
Descrição: dc.descriptionImmunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios.-
Descrição: dc.descriptionDepartment of Dermatology Hospital das Clínicas Universidade de São Paulo, SP-
Descrição: dc.descriptionDepartment of Dermatology Escola Paulista de Medicina Universidade Federal de São Paulo, SP-
Descrição: dc.descriptionState Health Secretariat of Ceará Centro de Dermatologia Dona Libânia, CE-
Descrição: dc.descriptionDepartment of Infectology Dermatology Imaging Diagnosis and Radiotherapy Faculty of Medicine Universidade Estadual Paulista, SP-
Descrição: dc.descriptionDepartment of Internal Medicine Dermatology Unit Faculty of Medicine Universidade Federal Fluminense, RJ-
Descrição: dc.descriptionDepartment of Infectology Dermatology Imaging Diagnosis and Radiotherapy Faculty of Medicine Universidade Estadual Paulista, SP-
Formato: dc.format167-180-
Idioma: dc.languageen-
Relação: dc.relationAnais Brasileiros de Dermatologia-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBiological products-
Palavras-chave: dc.subjectHepatitis, viral, human-
Palavras-chave: dc.subjectLeprosy-
Palavras-chave: dc.subjectMycosis fungoides-
Palavras-chave: dc.subjectPsoriasis-
Palavras-chave: dc.subjectTuberculosis-
Palavras-chave: dc.subjectVaccination-
Título: dc.titleInfections in the era of immunobiologicals-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.